Synact ready for phase II with arthritis candidate: "An important milestone for the company"
After finishing phase I trials, Danish biotech company Synact has applied for the authorities' permission to initiate a phase II study with the company's lead candidate against rheumatoid arthritis. According to the CEO, the company has various financing opportunities.
Danish biotech company Synact Pharma, which went public in Sweden in 2016, has applied for permission from Danish Medicines Agency and the National Committee on Health Research Ethics to initiate a larger phase II study with AP1189 - the company's candidate for treatment of rheumatoid arthritis.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
